Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.69 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 322.84 | 19.02 | 4.88 | 22.73 | 39.04 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.39 | 1.51 | 0.73 | 1.51 | 1.61 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CAMP4 Therapeutics Corporation's operating margin was -1717.1% in Q3 2025, down 846.8 pp QoQ. The trailing four-quarter average of -1566.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | 100.0% | 38.2% | 35.3% | 33.7% |
| — | — | — | — | — | — | — | — | — | +151.0% | -3.7% | -13.9% | -17.2% | |
| Operating Margin | -8142.3% | -1717.1% | -870.3% | -1526.8% | -2152.5% | — | — | — | — | -3525.1% | -3.5% | -2.0% | -4.6% |
| — | — | — | — | — | — | — | — | — | -47985.4% | +75.5% | +68.9% | +51.7% | |
| Net Margin | -7943.4% | -1899.2% | -840.8% | -1449.1% | -2036.7% | — | — | — | — | -3341.7% | -5.7% | -10.3% | -6.0% |
| — | — | — | — | — | — | — | — | — | -32375.4% | +69.8% | +23.3% | +63.9% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -82.0% | -37.8% | -27.5% | -21.7% | -21.0% | — | — | -82.8% | — | -101.7% | -30.1% | -49.0% | -23.4% |
| — | — | — | +73.8% | — | — | — | -68.9% | — | -241.9% | -28.8% | -315.4% | -74.2% | |
| ROA | -77.7% | -29.4% | -22.1% | -17.6% | -26.6% | -52.6% | -42.0% | -29.3% | -6.2% | -3.2% | -1.1% | -2.1% | -1.2% |
| — | +44.0% | +47.4% | +39.9% | -329.6% | -1554.1% | -3818.5% | -1294.3% | -398.0% | -58.1% | +66.3% | +9.0% | +55.3% | |
| ROIC | — | -126.3% | -107.5% | -109.9% | — | — | — | — | -33.7% | -4.3% | -0.9% | -0.5% | -1.3% |
| — | — | — | — | — | — | — | — | -2584.2% | -129.8% | +74.2% | +67.0% | +49.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 1103.8% YoY to 5.60x, strengthening the short-term liquidity position. Debt/Equity has risen for 4 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.18 | 0.18 | 0.15 | 0.14 | — | — | 0.70 | — | 22.56 | 19.62 | 16.81 | 13.19 |
| — | — | — | -78.2% | — | — | — | -95.8% | — | +105.6% | +127.6% | +516.1% | +405.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 80.27 | — | 155.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.92 | 5.60 | 5.60 | 8.02 | 6.92 | 0.47 | 1.90 | 1.90 | 5.13 | 1.74 | 1.69 | 1.64 | 1.68 |
| — | +1103.8% | +194.9% | +322.4% | +34.9% | -73.2% | +12.3% | +15.7% | +204.5% | -6.8% | -14.0% | -18.2% | -17.5% | |
| Quick Ratio | 6.92 | 5.60 | 5.60 | 8.02 | 6.92 | 0.47 | 1.90 | 1.90 | 5.13 | 1.43 | 1.45 | 1.42 | 1.47 |
| — | +1103.8% | +194.9% | +322.4% | +34.9% | -67.4% | +31.3% | +34.1% | +247.6% | -12.0% | -16.9% | -21.4% | -19.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | -9.56 | -7.84 | -1.50 | -0.98 | -2.21 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCAMP4 Therapeutics Corporation's current P/E is -1.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CAMP4 Therapeutics Corporation's current operating margin is -8142.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CAMP4 Therapeutics Corporation's business trajectory between earnings reports.